{"entity":{"id":"nct00433511","kind":"trial","name":"E5103 adjuvant chemotherapy with or without bevacizumab","aka":["Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"],"tldr":"E5103 compares chemotherapy after breast surgery with or without bevacizumab. It measures whether adding the drug changes the chance of cancer recurrence.","summary":"E5103 compares chemotherapy after breast surgery with or without bevacizumab. It measures whether adding the drug changes the chance of cancer recurrence.\n\nInterventional study registered as NCT00433511, sponsored by National Cancer Institute (NCI). Registry phase: 3. Registry enrollment is 4,994 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT00433511","url":"https://clinicaltrials.gov/study/NCT00433511"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT00433511"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","cyclophosphamide","doxorubicin","paclitaxel"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00433511","phase":"3","setting":"Node-positive or high-risk node-negative breast cancer after surgery","sponsor":"National Cancer Institute (NCI)","participation":[{"nct":"NCT00433511","source":"https://clinicaltrials.gov/study/NCT00433511","fetchedAt":"2026-10-10T20:54:21.093921Z","studySha256":"8d8e62914035de99ea3df2cc9a09db685a66f55c6f8bb967456394a84b22bb61","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"National Cancer Institute (NCI)","collaboratorCount":3,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":4994,"enrolmentType":"ACTUAL","siteCount":842,"recruitingSiteCount":0,"countries":["Peru","South Africa","United States"]}],"started":"2007-11-02","startedType":"actual","enrolled":4994,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00433511/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}